Company News

Happy Holidays from Complete Omics!

December 23, 2021 | BALTIMORE –

Dear Team Members and Friends:

2021 has been an exciting year for Complete Omics – – we brought dramatic improvements to biomedical sciences and patient care by advancing our multi-omics molecular diagnostic pipelines even further.  In the year of 2021, over 80 new research papers featuring Complete Omics’ technologies and platforms have been published.

Since 2021 summer, Complete Omics started to offer cutting-edge multi-omics research services backed up by our top profile publications and patents. Now we are thrilled to work with over 30 pharmaceutical corporations and over 50 research labs worldwide to implement our Complete360® multi-omics molecular diagnostic pipeline and our Valid-NEOTM companion diagnostics pipeline. Hundreds of novel biomarkers and dozens of new drug targets are identified and quantified by us, and numerous treatment approaches are being developed based on our discoveries.

We expect massive new features to be added on to our platforms over the next few years, and many exciting new discoveries ahead from ourselves and from the collaborations with scientists throughout the world.

Please follow our company’s progress or contact us at info@completeomics.com to learn more about how we can advance your research and patient care.

All of us at Complete Omics wish you a Merry Christmas and Happy New Year of 2022!

Read more

Complete Omics Announces that Dr. Hui Zhang has joined the Company’s Board of Advisors

July 1, 2021 | BALTIMORE –  Complete Omics today announced that Hui Zhang, PhD, has joined the Company’s Board of Advisors, effective July 1st, 2021. Dr. Zhang joins the Complete Omics Board of Advisors with extensive experience in basic and clinical proteomics and cancer research.

Read more

Complete Omics Announces that Dr. Ben Orsburn has joined the Company’s Board of Advisors

October 1, 2021 | BALTIMORE –  Complete Omics today announced that Benjamin Orsburn, PhD, has joined the Company’s Board of Advisors, effective Oct 1st, 2021. Dr. Orsburn joins the Complete Omics Board of Advisors with fruitful research and business experience in proteomics applications and his deep vision in latest developments of proteomics assays.

Read more

Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media

Complete Omics’ Clinical Proteomics team is proud to share with you the recent media coverage of our efforts in paving the way for the ultimate personalized cancer therapeutics. Our efforts toward achieving this ultimate goal of cancer treatment were reported by GenomeWeb, The Scientist, Precision Oncology News, News Wise, Fierce Biotech, etc. One of our clinical proteomics pipelines can help identify personalized cancer neoantigens that can be further targeted by a variety of therapeutic approaches, such as mRNA cancer vaccine, therapeutic peptide injection, engineering cell therapy, and here two bispecific antibody approaches.

Read more >
Read more

Complete Omics published novel technologies on SCIENCE and SCIENCE IMMUNOLOGY.

Complete Omics Inc. (official website) – For years, personalized cancer therapeutics has been an ultimate goal for all cancer patients and doctors. Healthcare providers and scientists working across the biopharmaceutical industry have been tirelessly committed to bringing to patients more and more, better and better, personalized cancer therapeutic approaches.

Complete Omics has been a pioneer in multi-omics molecular diagnostics since founded and we are humbled and excited to share with you two of the milestones in personalized cancer diagnostics and treatment through our multi-omics platform that we have published on Science Immunology and Science.

Read more >
Read more

Congratulations to our lab alumni founders in Thrive Earlier Detection.

NEW YORK – Exact Sciences has entered into a definitive agreement to acquire liquid biopsy test developer Thrive Earlier Detection, a molecular diagnostics company founded by Vogelstein lab trainees from Johns Hopkins, for cash and stock consideration of up to $2.15 billion.

Read more >
Read more

MANA-SRM pipeline and its application in personalized cancer therapeutics.

NEW YORK – Researchers at Johns Hopkins University have developed a targeted mass spec method for measuring cancer-linked neoantigens.

Described in a study published last month in Cancer Immunology Research, the method could prove useful both for studying tumor immunology and in the development of personalized cancer immunotherapies, said Qing Wang, first author on the paper and founder and CEO of clinical omics firm Complete Omics.

Read more >
Read more

SAFE-SRM, 1st pipeline for clinical proteomics

NEW YORK (GenomeWeb) – Researchers in the lab of Johns Hopkins University professor Bert Vogelstein have identified a pair of potential peptide biomarkers for ovarian cancer.

Described in a study published this week in Proceedings of the National Academy of Sciences, the markers stem from efforts by the lab, which had traditionally focused on cancer genomics, to move more seriously into the proteomic and protein biomarker space, said Qing Wang, a faculty member in Vogelstein’s lab and first author on the study.

The peptide markers were validated using a selected-reaction monitoring system developed by Wang and his colleagues that uses light-labeled peptides and extensive fractionation to enable highly sensitive and reproducible quantitation of candidate biomarkers in plasma.

Read more >
Read more

MT-SRM, direct detection of mutant proteins as cancer-specific biomarkers

Cancer biomarkers are currently the subject of intense research because of their potential utility for diagnosis, prognosis, and targeted therapy. In theory, the gene products resulting from somatic mutations are the ultimate protein biomarkers, being not simply associated with tumors but actually responsible for tumorigenesis. In 2010, we developed the 1st pipeline for detecting and quantifying mutant protein as cancer specific biomarkers from human specimens, and it received a broad range of attentions from different disciplines of biomedical sciences [Ref. 1].

Read more >
Read more
Follow by Email
Facebook
Twitter
LinkedIn